Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):372-85

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  NEWS AND VIEWS ON CLINICAL NEUROIMAGING 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):372-85

DOI: 10.23736/S1824-4785.17.03018-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Clinical utility and research frontiers of neuroimaging in movement disorders

Flavio NOBILI 1 , Eric WESTMAN 2, Rosalie V. KOGAN 3, Joana B. PEREIRA 2, Federico MASSA 1, Matteo GRAZZINI 1, Sanne K. MELES 4, Klaus L. LEENDERS 3, 4

1 Deparment of Neuroscience (DINOGMI), IRCCS Polyclinic San Martino-IST, University of Genoa, Genoa, Italy; 2 Division of Clinical Geriatrics, Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden; 3 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), Groningen, The Netherlands; 4 Department of Neurology, University Medical Center Groningen (UMCG), Groningen, The Netherlands


PDF


Neuroimaging in Parkinson’s disease (PD) and other primary Parkinsonian disorders has been increasingly used in the routine clinical work in the last years. The paradigm has changed from an “exclusionary” use, i.e., to rule out causes of secondary Parkinsonism, to an “inclusionary” one, i.e., finding image and network characteristics allowing to identify a specific disease. This is allowed by analyses spanning from the commonly used visual analysis to the most sophisticated postprocessing leading to the identification of covariance patterns both in morphological and functional neuroimaging. However, paralleling the advancement in covariance and connectivity analyses, the issues of standardization and harmonization of data acquisition, and image reconstruction and postprocessing among centers are emerging in the scientific community. Also, the building of scientific evidence still suffers from the lack of large, formal studies and relies on relatively small cohort studies from one or few centers. Joint actions to face these issues are now ongoing in Europe, supported by specific programs, such as the Joint Programming on Neurodegenerative Diseases (JPND). In the present review, some of the most recent and relevant achievements in the field of diffusion tensor magnetic resonance imaging (MRI), functional MRI, fludeoxyglucose-positron-emission tomography, dopamine transporter single-photon emission computed tomography and non-dopaminergic imaging in PD and primary Parkinsonisms are reported.


KEY WORDS: Parkinson disease - Parkinsonian disorders - Magnetic resonance imaging - Fluorodeoxyglucose F18 - Positron-emission tomography - Tomography, emission-computed, single-photon

top of page